Lund, Sweden

Tomas Fex

This inventor holds 2 USPTO granted patents. Top assignee: Other. Active years: 1990.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tomas Fex. Retrieved from https://idiyas.com/inventor/tomas-fex-batcrkwc

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 18(Granted Patents)


Company Filing History:

goldMedal2 out of 834,570 
Other
 patents

Years Active: 1990

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations by Inventor Tomas Fex

Introduction

Tomas Fex is a notable inventor based in Lund, Sweden. He has made significant contributions to the field of neuropharmacology, focusing on the development of compounds aimed at treating mental disorders. With a total of 2 patents, his work is recognized for its potential impact on mental health treatments.

Latest Patents

Tomas Fex's latest patents include "Bisphenylalkylpiperazine derivatives, a method of their preparation" and "Novel 1-piperazinecarboxamide derivatives." The latter patent describes a series of 1-piperazinecarboxamide derivatives that serve as neuropharmacological agents intended for the treatment of mental disorders, such as psychoses and depression.

Career Highlights

Throughout his career, Tomas has focused on innovative solutions in the pharmaceutical industry. His research has led to the development of compounds that could significantly improve the quality of life for individuals suffering from mental health issues.

Collaborations

Tomas has collaborated with notable colleagues, including Knut G Olsson and Aina L Abramo. Their combined expertise has contributed to the advancement of research in neuropharmacology.

Conclusion

Tomas Fex's contributions to the field of neuropharmacology through his patents highlight his commitment to addressing mental health challenges. His innovative work continues to pave the way for future advancements in treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…